Evidence map›Paper›PMID 16103896›Full record

Trial reportThe pharmacogenomics journal2005

An association study of 43 SNPs in 16 candidate genes with atorvastatin response.

J F Thompson, M Man, K J Johnson, L S Wood, M E Lira, D B Lloyd, P Banerjee, P M Milos, S P Myrand, J Paulauskis and 2 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The pharmacogenomics journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 8 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 8 syntheses or guidelines pooled it, 213 citations in OpenAlex.

  1. Pooled it
  2. Pravastatin for lowering lipids.The Cochrane database of systematic reviews · 2023 · on this map
    Pooled it
  3. Pitavastatin for lowering lipids.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  4. Cerivastatin for lowering lipids.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  5. Fluvastatin for lowering lipids.The Cochrane database of systematic reviews · 2018
    Pooled it
  6. Lipid-lowering efficacy of atorvastatin.The Cochrane database of systematic reviews · 2015 · on this map
    Pooled it
  7. Lipid-lowering efficacy of rosuvastatin.The Cochrane database of systematic reviews · 2014 · on this map
    Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.Arteriosclerosis, thrombosis, and vascular biology · 2010 · on this map
    Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

J F ThompsonDiscovery Pharmacogenomics, Pfizer Global Research and Development, Eastern Point Road, MS8118D-3069, Groton, CT 06340, USA. john.f.thompson@pfizer.com
M Man
K J Johnson
L S Wood
M E Lira
D B Lloyd
P Banerjee
P M Milos
S P Myrand
J Paulauskis
M A Milad
W J Sasiela
Pfizer (United States) · USManhattan Institute for Policy Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variation in individual response to statin therapy has been widely studied for a potential genetic component. Multiple genes have been identified as potential modulators of statin response, but few study findings have replicated. To further examine these associations, 2735 individuals on statin therapy, half on atorvastatin and the other half divided among fluvastatin, lovastatin, pravastatin and simvastatin were genotyped for 43 SNPs in 16 genes that have been implicated in statin response. Associations with low-density lipoprotein cholesterol (LDL-C) lowering, total cholesterol lowering, HDL-C elevation and triglyceride lowering were examined. The only significant associations with LDL-C lowering were found with apoE2 in which carriers of the rare allele who took atorvastatin lowered their LDL-C by 3.5% more than those homozygous for the common allele and with rs2032582 (S893A in ABCB1) in which the two groups of homozygotes differed by 3% in LDL-C lowering. These genetic effects were smaller than those observed with the demographic variables of age and gender. The magnitude of all the differences found is sufficiently small that genetic data from these genes should not influence clinical decisions on statin administration.

Indexed as

AgedApolipoprotein E2Apolipoproteins EAtorvastatinCholesterol, HDLCholesterol, LDLFemaleGene FrequencyHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesMaleMiddle AgedPolymorphism, Single NucleotidePyrrolesApolipoprotein E2Apolipoproteins EAtorvastatinCholesterol, HDLCholesterol, LDLHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesPyrrolesTriglycerides

Identifiers

PMID16103896
OpenAlexW1970750464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.